ASCO 2024 | Phase I/II trial of AdAPT-001, an oncolytic virus, and a checkpoint inhibitor in solid tumors
Lucy Kennedy
• 2 Jun 2024
Lucy Kennedy, MD, Cleveland Clinic, Cleveland, OH, presents findings from a Phase I/II trial (NCT04673942) of AdAPT-001, an oncolytic virus combined with a TGF-β trap, with a checkpoint inhibitor in various immune refractory solid tumors such as sarcoma, breast cancer and melanoma. Combination therapy of AdAPT-001 with a checkpoint inhibitor resulted in promising response rates, where TGF-β activity was suppressed. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
